株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

寒冷凝集素症(CAD)- 疫学予測 2028年

Cold Agglutinin Disease (CAD) - Epidemiology Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 911520
出版日 ページ情報 英文 91 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
寒冷凝集素症(CAD)- 疫学予測 2028年 Cold Agglutinin Disease (CAD) - Epidemiology Forecast - 2028
出版日: 2019年09月01日 ページ情報: 英文 91 Pages
概要

当レポートでは、新興10カ国(トルコ、ロシア、サウジアラビア、アラブ首長国連邦、メキシコ、コロンビア、ブラジル、アルゼンチン、中国、台湾)の寒冷凝集素症(CAD)市場を調査し、市場および疾患の概要、性別・病型・年齢別の有病数の推移と予測を詳細にまとめています。

目次

第1章 重要洞察

第2章 患者概要

  • 分布状況(実績値)
  • 分布状況(予測値)

第3章 寒冷凝集素症(CAD):疾病背景と概要

  • イントロダクション
  • 兆候と症状
  • クローン性と組織病理学
  • 病因
  • 診断

第4章 疫学および患者人口:地域別

  • 主な調査結果

第5章 新興10カ国の疫学

  • 新興10カ国の寒冷凝集素症(CAD)の有病数

第6章 寒冷凝集素症(CAD)の疫学:地域別

  • 仮定と根拠
  • アジア
    • 台湾
      • 寒冷凝集素症(CAD)の有病数
      • 寒冷凝集素症(CAD)の有病数:性別
      • 寒冷凝集素症(CAD)の有病数:病型別
      • 寒冷凝集素症(CAD)の有病数:年齢別
    • 中国
      • 寒冷凝集素症(CAD)の有病数
      • 寒冷凝集素症(CAD)の有病数:性別
      • 寒冷凝集素症(CAD)の有病数:病型別
      • 寒冷凝集素症(CAD)の有病数:年齢別
  • 中東
    • サウジアラビア
      • 寒冷凝集素症(CAD)の有病数
      • 寒冷凝集素症(CAD)の有病数:性別
      • 寒冷凝集素症(CAD)の有病数:病型別
      • 寒冷凝集素症(CAD)の有病数:年齢別
    • アラブ首長国連邦
      • 寒冷凝集素症(CAD)の有病数
      • 寒冷凝集素症(CAD)の有病数:性別
      • 寒冷凝集素症(CAD)の有病数:病型別
      • 寒冷凝集素症(CAD)の有病数:年齢別
  • 東欧
    • ロシア
      • 寒冷凝集素症(CAD)の有病数
      • 寒冷凝集素症(CAD)の有病数:性別
      • 寒冷凝集素症(CAD)の有病数:病型別
      • 寒冷凝集素症(CAD)の有病数:年齢別
    • トルコ
      • 寒冷凝集素症(CAD)の有病数
      • 寒冷凝集素症(CAD)の有病数:性別
      • 寒冷凝集素症(CAD)の有病数:病型別
      • 寒冷凝集素症(CAD)の有病数:年齢別
  • ラテンアメリカ
    • メキシコ
      • 寒冷凝集素症(CAD)の有病数
      • 寒冷凝集素症(CAD)の有病数:性別
      • 寒冷凝集素症(CAD)の有病数:病型別
      • 寒冷凝集素症(CAD)の有病数:年齢別
    • ブラジル
      • 寒冷凝集素症(CAD)の有病数
      • 寒冷凝集素症(CAD)の有病数:性別
      • 寒冷凝集素症(CAD)の有病数:病型別
      • 寒冷凝集素症(CAD)の有病数:年齢別
    • アルゼンチン
      • 寒冷凝集素症(CAD)の有病数
      • 寒冷凝集素症(CAD)の有病数:性別
      • 寒冷凝集素症(CAD)の有病数:病型別
      • 寒冷凝集素症(CAD)の有病数:年齢別
    • コロンビア
      • 寒冷凝集素症(CAD)の有病数
      • 寒冷凝集素症(CAD)の有病数:性別
      • 寒冷凝集素症(CAD)の有病数:病型別
      • 寒冷凝集素症(CAD)の有病数:年齢別

第7章 アンメットニーズ

第8章 市場の成長要因

第9章 市場の障壁

第10章 キーオピニオンリーダーの見解

第11章 付録

  • 報告方法

第12章 DelveInsightのサービス内容

第13章 免責事項

第14章 DelveInsightについて

図表

List of Tables

  • Table 1: Autoimmune Hemolytic Anemia Consists of Warm, Cold, or Mixed Reactive Antibodies
  • Table 2: Diagnostic criteria for cold agglutinin disease
  • Table 3: Total Prevalence of Cold agglutinin disease in 10 Emerging Markets (2017-2028)
  • Table 4: Prevalent Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Table 5: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Table 6: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Table 7: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Table 8: Prevalent Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Table 9: Gender-specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Table 10: Type-Specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Table 11: Age-Specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Table 12: Prevalent Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Table 13: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Table 14: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Table 15: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Table 16: Prevalent Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Table 17: Gender-specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Table 18: Type-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Table 19: Age-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Table 20: Prevalent Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Table 21: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Table 22: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Table 23: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Table 24: Prevalent Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Table 25: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Table 26: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Table 27: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Table 28: Prevalent Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Table 29: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Table 30: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Table 31: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Table 32: Prevalent Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Table 33: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Table 34: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Table 35: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Table 36: Prevalent Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Table 37: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Table 38: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Table 39: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Table 40: Prevalent Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Table 41: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Table 42: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Table 43: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)

List of Figures

  • Figure 1: Common symptoms of cold agglutinin disease
  • Figure 2: The complement cascade
  • Figure 3: Complement-mediated hemolysis in cold agglutinin disease
  • Figure 4: Total Prevalence of Cold agglutinin disease in 10 Emerging Markets (2017-2028)
  • Figure 5: Prevalent Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Figure 6: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Figure 7: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Figure 8: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan (2017-2028)
  • Figure 9: Prevalent Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Figure 10: Gender-specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Figure 11: Type-Specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Figure 12: Age-Specific Cases of Cold Agglutinin Disease (CAD) in China (2017-2028)
  • Figure 13: Prevalent Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Figure 14: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Figure 15: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Figure 16: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia (2017-2028)
  • Figure 17: Prevalent Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Figure 18: Gender-specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Figure 19: Type-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Figure 20: Age-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE (2017-2028)
  • Figure 21: Prevalent Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Figure 22: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Figure 23: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Figure 24: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Russia (2017-2028)
  • Figure 25: Prevalent Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Figure 26: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Figure 27: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Figure 28: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey (2017-2028)
  • Figure 29: Prevalent Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Figure 30: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Figure 31: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Figure 32: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico (2017-2028)
  • Figure 33: Prevalent Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Figure 34: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Figure 35: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Figure 36: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil (2017-2028)
  • Figure 37: Prevalent Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Figure 38: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Figure 39: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Figure 40: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina (2017-2028)
  • Figure 41: Prevalent Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Figure 42: Gender-specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Figure 43: Type-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Figure 44: Age-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia (2017-2028)
  • Figure 45: Therapeutic pathway for cold agglutinin disease
  • Figure 46: Unmet Needs
  • Figure 68: Market Drivers
  • Figure 69: Market Barriers
目次
Product Code: DIEI0384

DelveInsight's 'Cold Agglutinin Disease (CAD)- Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of CAD in 10 Emerging Markets (EM) i.e. Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China, and Taiwan.

Geography Covered

  • Asia (Taiwan and China)
  • Middle East (Saudi Arabia and UAE)
  • Eastern Europe (Russia and Turkey)
  • LATAM (Mexico, Brazil, Argentina, and Colombia)

Study Period: 2017-2028

CAD - Disease Understanding and Treatment Algorithm

CAD is a type of autoimmune hemolytic anemia (AIHA) which consist of warm, cold, or mixed-reactive antibody types that are directed against antigens on the red blood cell (RBC) surface. The autoantibodies may be idiopathic or related to an underlying condition, such as infection, malignancy, or immune disease.

Thus, based on the autoantibodies, CAD is classified as primary (unknown cause) or secondary (caused by an underlying condition). Primary Cold Agglutinin Disease is used to describe patients without other systemic autoimmune disease or infective etiology and who have no clinical or radiological evidence of underlying lymphoma. Secondary Cold Agglutinin Disease, is mediated by hemolytic anemia occasionally complicating other specific diseases, such as B cell neoplasias (CLL, Waldenstrom macroglobulinemia, myeloma, other lymphomas), solid tumors (squamous carcinoma of the lung, metastatic adenocarcinoma of the colon, basal cell carcinoma, metastatic adrenal carcinoma, mixed parotid tumor), infections (most frequently Mycoplasma pneumonia, Epstein-Barr virus) or autoimmune diseases (scleroderma, primary Sjogren's syndrome, adult Still's disease, SLE, rheumatoid arthritis). The responsible antibody is monoclonal IgM in B-cell neoplasias and solid tumors and polyclonal IgM in infections, connective tissue diseases, and non-Hodgkin lymphomas.

CAD Epidemiology

The CAD epidemiology division provides insights about historical and current patient pool and forecasted trends of 10EM countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent cases, Gender-Specific Prevalence, Age-Specific Prevalence and Type-Specific Prevalent cases of CAD ) scenario of CAD in 10 Emerging Markets (EM) i.e. Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China and Taiwan for the study period 2017-2028.

According to DelveInsight, the total prevalent cases of CAD in the 10EM was found to be 29,077 in 2017. The total prevalent cases for Cold Agglutinin Disease (CAD) were highest in China, while Russia and U.A.E. accounted for the least number of prevalent cases. In the case of Type-Specific cases, Primary CAD and Secondary CAD are reported in nearly equal proportions in all the 10EM countries. However, Primary CAD is commonly observed and easily treated in comparison to secondary CAD. The prevalence of CAD in the 10EM is expected to increase during the study period of 2017-2028.

CAD Report Insights

  • The report covers a descriptive overview of the CAD, explaining its signs and symptoms, clonality and histopathology, pathogenesis and diagnosis.
  • Comprehensive insight has been provided into the epidemiology CAD in the 10EM countries covering Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China, and Taiwan.
  • Assesses growth opportunities in 10EM countries with respect to the patient population.

CAD Report Key Strengths

  • 10-Year Forecast
  • 10 EM Coverage
  • Epidemiology Segmentation by Type of CAD
  • Total Patient Pool of CAD
  • Gender-Specific Diagnosed Patient Pool of CAD
  • Age-Specific Diagnosed Patient Pool of CAD
  • Type-Specific Diagnosed Patient Pool of CAD

CAD Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles

Key Benefits

  • Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by type

Table of Contents

1. Key Insights

2. Cold Agglutinin Disease: Patient Overview at a Glance

  • 2.1. Patient Share (%) Distribution of Cold Agglutinin Disease in 2017
  • 2.2. Patient Share (%) Distribution of Cold Agglutinin Disease in 2028

3. Cold Agglutinin Disease: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Clonality and Histopathology
  • 3.4. Pathogenesis
  • 3.5. Diagnosis

4. Epidemiology and Patient Population - By Region

  • 4.1. Key Findings

5. Ten Emerging Markets (10EM) - Epidemiology

  • 5.1. Total Prevalence of Cold agglutinin disease in 10 Emerging Markets

6. Region Wise-Epidemiology of Cold Agglutinin Disease (CAD)

  • 6.1. Assumptions and Rationale
  • 6.2. Asia [Taiwan and China]
  • 6.3. Taiwan
    • 6.3.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Taiwan
    • 6.3.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan
    • 6.3.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan
    • 6.3.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan
  • 6.4. China
    • 6.4.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in China
    • 6.4.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in China
    • 6.4.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in China
    • 6.4.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in China
    • 6.4.5. Middle East [Saudi Arabia and UAE]
  • 6.5. Saudi Arabia
    • 6.5.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
    • 6.5.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
    • 6.5.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
    • 6.5.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
  • 6.6. UAE
    • 6.6.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in the UAE
    • 6.6.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE
    • 6.6.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE
    • 6.6.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE
  • 6.7. Eastern Europe [Russia and Turkey]
  • 6.8. Russia
    • 6.8.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Russia
    • 6.8.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Russia
    • 6.8.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Russia
    • 6.8.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Russia
  • 6.9. Turkey
    • 6.9.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Turkey
    • 6.9.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey
    • 6.9.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey
    • 6.9.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey
  • 6.10. LATAM [Mexico, Brazil, Argentina and Colombia]
  • 6.11. Mexico
    • 6.11.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Mexico
    • 6.11.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico
    • 6.11.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico
    • 6.11.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico
  • 6.12. Brazil
    • 6.12.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Brazil
    • 6.12.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil
    • 6.12.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil
    • 6.12.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil
  • 6.13. Argentina
    • 6.13.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Argentina
    • 6.13.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina
    • 6.13.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina
    • 6.13.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina
  • 6.14. Colombia
    • 6.14.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Colombia
    • 6.14.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia
    • 6.14.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia
    • 6.14.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia

7. Unmet Needs

8. Market Drivers

9. Market Barriers

10. KOL Views

11. Appendix

  • 11.1. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

Back to Top